New Additions to Drugs.com for 2024
The following 50 drugs were added to the Drugs.com database in 2024.
Alyftrek
Dec 27, 2024 - Alyftrek is a triple combination CFTR modulator that is used to treat cystic fibrosis (CF) in people aged 6 years and older with at least one F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
Crenessity
Dec 22, 2024 - Crenessity is a selective corticotropin-releasing factor (CRF) type 1 receptor antagonists that is used to control androgen levels (a testosterone-like hormone) in adults and children 4 years of age and older with classic congenital adrenal hyperplasia (CAH), in addition to glucocorticoids.
Ensacove
Dec 20, 2024 - Ensacove is an oral kinase inhibitor that may be used to treat non-small cell lung cancer (NSCLC) in adults that has spread and is caused by an abnormal ALK gene.
Steqeyma
Dec 20, 2024 - Steqeyma (ustekinumab-stba) is an interluekin inhibitor that is a Stelara biosimilar which may be used to treat Crohn's disease, ulcerative colitis, moderate to severe plaque psoriasis, and active psoriatic arthritis.
Yesintek
Dec 4, 2024 - Yesintek a biosimilar to Stelara, is used to treat moderate to severe plaque psoriasis, active psoriatic arthritis, or moderately to severely active Crohn's disease or ulcerative colitis in adults.
Revuforj
Nov 20, 2024 - Revuforj is used to treat acute leukemia with a lysine methyltransferase 2A gene translocation (KMT2A) in adults and children 1 year and older whose disease has come back or has not improved after previous treatment(s).
Danziten
Nov 18, 2024 - Danziten is a kinase inhibitor that is used to treat Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in adults. Danziten is equivalent in effectiveness to Tasigna, but its formulation means patients do not need to take it in a fasting state.
Aucatzyl
Nov 11, 2024 - Aucatzyl is a CAR-T cell treatment for acute lymphoblastic leukemia (ALL) in adults that is made by genetically modifying a person’s white blood cells to recognize and attack leukemic cells.
Emrosi
Nov 5, 2024 - Emrosi is used to treat rosacea in adults and is a low-dose modified-release form of the antibiotic minocycline.
Imuldosa
Oct 14, 2024 - Imuldosa (ustekinumab-srlf) is an injectable prescription medicine which is a biosimilar to Stelara that may be used to treat certain types of plaque psoriasis, active psoriatic arthritis, Crohn’s disease, and ulcerative colitis, which are all autoimmune conditions.
Hympavzi
Oct 13, 2024 - Hympavzi (marstacimab-hncq) may be used to prevent or reduce the frequency of bleeding episodes in adults or children aged 12 years of age and older with hemophilia A or B without inhibitors. It is administered once weekly subcutaneously (under the skin) using the Hympavzi autoinjector pen or syringe.
Flyrcado
Oct 1, 2024 - Flyrcado (flurpiridaz F 18) is a radioactive diagnostic drug that may be used for PET MPI in adults with known or suspected CAD to evaluate for myocardial ischemia and myocardial infarction. Flyrcado may be used at rest or under stress testing (using medications or exercise).
Otulfi
Oct 1, 2024 - Otulfi (ustekinumab), a biosimilar to Stelara, may be used to treat Crohn's disease, ulcerative colitis, moderate to severe plaque psoriasis, and active psoriatic arthritis. Otulfi is the fourth Stelara biosimilar to be approved.
Tecentriq Hybreza
Sep 23, 2024 - Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) may be used to treat certain patients with non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), hepatocellular carcinoma (HCC), melanoma, and alveolar soft part sarcoma.
Pavblu
Sep 2, 2024 - Pavblu (aflibercept-ayyh) is a biosimilar to Eylea that may be used to treat the following eye conditions: neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), and diabetic retinopathy (DR). Pavblu is given as an injection directly into the eye once every 4 to 8 weeks.
Livdelzi
Aug 15, 2024 - Livdelzi (seladelpar) is an oral prescription medicine that may be used to treat primary biliary cholangitis (PBC) in adults. Livdelzi is taken in combination with ursodeoxycholic acid (UDCA) in adults who have not responded well to UDCA, or used alone in patients unable to tolerate UDCA.
Yorvipath
Aug 13, 2024 - Yorvipath (palopegteriparatide) is an injectable parathyroid hormone replacement therapy that can be used to treat adults with low parathyroid hormone levels (hypoparathyroidism). Yorvipath is self-administered subcutaneously (under the skin) using a prefilled pen once a day.
Crexont
Aug 12, 2024 - Crexont (carbidopa and levodopa) is an extended-release capsule that may be used to treat symptoms of Parkinson's disease, such as stiffness or tremors. It may also be used to treat Parkinson's symptoms caused by carbon monoxide poisoning or manganese intoxication in adults.
Lymphir
Aug 9, 2024 - Lymphir (denileukin diftitox-cxdl) is an injectable targeted cancer treatment that may be used to treat adults with cutaneous T-cell lymphoma (CTCL) that has returned or persisted despite treatment.
Epysqli
Jul 24, 2024 - Epysqli (eculizumab-aagh), a biosimilar to Soliris, targets the complement system to treat paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Pyzchiva
Jul 3, 2024 - Pyzchiva (ustekinumab-ttwe) is an injectable human interleukin-12 and 23 blocker which is a biosimilar to Stelara that may be used to treat certain types of plaque psoriasis, active psoriatic arthritis, Crohn’s disease, and ulcerative colitis.
Ahzantive
Jul 2, 2024 - Ahzantive (aflibercept-mrbb) is a biosimilar to Eylea that may be used to treat the following eye conditions: neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), and diabetic retinopathy (DR). Ahzantive is given as an injection directly into the eye once every 4 to 8 weeks.
Ohtuvayre
Jun 27, 2024 - Ohtuvayre (ensifentrine) is an inhaled dual phosphodiesterase treatment that may be used to improve symptoms and reduce the number of flare-ups of chronic obstructive pulmonary disease (COPD) in adults. It must be used with a nebulizer and it is not intended as a rescue treatment to relieve sudden breathing problems.
Sofdra
Jun 21, 2024 - Sofdra by Botanix is an anticholinergic topical gel that is applied directly to the underarm area and may be used to treat excessive underarm sweating (primary axillary hyperhidrosis) in adults and children aged 9 years and older.
Yimmugo
Jun 19, 2024 - Yimmugo (immune globulin intravenous, human-dira) is an immune globulin 10% liquid given by intravenous (into a vein) infusion that may be used to treat primary humoral immunodeficiency (PI) in adults and children 2 years of age or older. It is usually given every 3 to 4 weeks.
Iqirvo
Jun 11, 2024 - Iqirvo (elafibranor) is an oral, once-daily, PPAR agonist that may be used to treat primary biliary cholangitis in combination with ursodeoxycholic acid (UDCA) in adults who have not responded well to UDCA, or used alone in patients unable to tolerate UDCA.
Rytelo
Jun 9, 2024 - Rytelo (imetelstat) is an injectable telomerase inhibitor that may be used to treat adults with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia.
mResvia
Jun 4, 2024 - mResvia is an RSV vaccine that may be used to protect adults aged 60 years and older against lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV). It is given as a single injection, usually into the muscle of the upper arm.
Bkemv
May 30, 2024 - Bkemv (eculizumab-aeeb) is an injectable complement inhibitor that is an interchangeable biosimilar to Soliris which may be used to treat paroxysmal nocturnal hemoglobinuria (PNH) and inhibit complement-mediated thrombotic microangiopathy (TMA) in adults and children with atypical hemolytic uremic syndrome (aHUS).
Yesafili
May 21, 2024 - Yesafili (aflibercept-jbvf) is an interchangeable biosimilar to Eylea that may be used to treat neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), and diabetic retinopathy (DR).
Myhibbin
May 7, 2024 - Myhibbin is a ready-to-use oral suspension of mycophenolate mofetil that may be used to prevent organ rejection in adults and children aged 3 months and older who have received an allogenic kidney, heart, or liver transplant. Myhibbin is used in combination with other immunosuppressants.
Rezenopy
May 1, 2024 - Rezenopy (naloxone hydrochloride) is a nasal spray that may be used for the temporary treatment of an opioid emergency such as an overdose or a possible opioid overdose with signs of breathing problems and severe sleepiness or not being able to respond in adults or children. Follow up with emergency medical help right away after giving the first dose of Rezenopy nasal spray, even if the person wakes up.
Libervant
May 1, 2024 - Libervant (diazepam) is an oral benzodiazepine film that may be used short-term to treat children aged 2 to 5 years with seizure clusters (also known as “acute repetitive seizures”) that are different from their usual seizure pattern. Libervant is placed on the inside of a child’s cheek (buccally).
Beqvez
May 1, 2024 - Beqvez (fidanacogene elaparvovec-dzkt) is an one-time, injectable, viral vector-based gene therapy that may be used to treat moderate to severe hemophilia B (congenital factor IX deficiency) in adult males who currently use factor IX prophylaxis therapy, or have current or a history of life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes, and, do not have neutralizing antibodies to adeno-associated virus serotype Rh74var (AAVRh74var) capsid as detected by an FDA-approved test.
Xolremdi
Apr 30, 2024 - Xolremdi (mavorixafor) is an oral CXC chemokine receptor 4 antagonist that may be used to increase the number of circulating mature neutrophils and lymphocytes in adults and children 12 years of age and older with WHIM syndrome.
Pivya
Apr 29, 2024 - Pivya (pivmecillinam) is an oral penicillin-type antibiotic that may be used to treat uncomplicated urinary tract infections (UTIs) in females aged 18 years and older that are caused by susceptible isolates of Escherichia coli, Proteus mirabilis, and Staphylococcus saprophyticus.
Xromi
Apr 23, 2024 - Xromi (hydroxyurea) is an oral solution that may be used to reduce the frequency of painful crises and reduce the need for blood transfusions in children aged 6 months to less than 2 years old, with sickle cell anemia who have recurrent moderate to severe painful crises.
Risvan
Apr 5, 2024 - Risvan (risperidone intramuscular) is an extended-release injectable, atypical, antipsychotic that is given by a healthcare provider once a month and may be used to treat schizophrenia in adults.
Voydeya
Apr 2, 2024 - Voydeya (danicopan) is an oral complement factor D inhibitor that may be used to treat extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH) as add-on therapy to ravulizumab (Ultomiris) or eculizumab (Soliris) when patients have had an insufficient response to these treatments.
Winrevair
Mar 28, 2024 - Winrevair (sotatercept) is an injectable activin signaling inhibitor that can be self-administered subcutaneously and may be used to treat adults with pulmonary arterial hypertension (PAH, WHO Group 1). Winrevair can improve your ability to exercise, improve your ability to perform normal activities with fewer symptoms and reduce the risk of your physical condition and symptoms worsening.
Pemgarda
Mar 26, 2024 - Pemgarda (pemivibart) is an unapproved, injectable, antiviral, human monoclonal antibody that has received emergency use authorization (EUA) for the prevention of COVID-19 in high-risk immunocompromised adults and adolescents 12 years of age and older who weigh at least 40kg. Candidates cannot be currently infected with SARS-CoV-2 or have had a known recent exposure to an individual infected with SARS-CoV-2, and must be moderately to severely immune compromised due to a medical condition (such as blood cancer) or receipt of immunosuppressive medications or treatments (such as an organ transplant) and be unlikely to mount an adequate immune response to COVID-19 vaccination.
Tryvio
Mar 25, 2024 - Tryvio (aprocitentan) is a once-daily, dual oral ERA that may be used to treat high blood pressure that is not adequately controlled by other high blood pressure medications. It is used in combination with other antihypertensives and reportedly has a low potential for drug interactions.
Edurant and Edurant Ped
Mar 19, 2024 - Edurant (rilpivirine tablets) and Edurant Ped (rilpivirine tablets for oral suspension) may be used to treat previously untreated HIV-1 infection in adults and children aged 2 years of age and older, weighing at least 14 kg, with HIV-1 RNA less than or equal to 100,000 copies/mL. They are used in combination with other antiretroviral agents.
Tevimbra
Mar 15, 2024 - Tevimbra is an immunotherapy treatment called a checkpoint inhibitor that is used to treat adults with esophageal, gastric, or gastroesophageal junction cancer that has spread (metastasized) or cannot be surgically removed.
Rezdiffra
Mar 15, 2024 - Rezdiffra (resmetirom) is an oral (taken by mouth) THR-beta agonist that may be used to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. It should be used alongside diet and exercise.
Tyenne
Mar 10, 2024 - Tyenne (tocilizumab-aazg) is an injectable interleukin-6 (IL-6) receptor antagonist that may be used to treat adults with moderately to severely active rheumatoid arthritis, Giant Cell Arteritis (GCA), or who are hospitalized with COVID-19 and severely ill; and adults and children 2 years and older with Polyarticular Juvenile Idiopathic Arthritis (PJIA), active systemic juvenile idiopathic arthritis (SJIA) and chimeric antigen receptor (CAR) T cell-induced, severe or life-threatening cytokine release syndrome (CRS). Tyenne is a biosimilar to Actemra, and can be given either subcutaneously (under the skin) or into a vein (IV).
Wyost
Mar 6, 2024 - Wyost (denosumab-bbdz) is an injection that is administered subcutaneously (under the skin) by a healthcare provider for the prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors; the treatment of giant cell tumor of the bone that cannot be removed by surgery or when surgery is too risky in adults and adolescents who have fully grown; and the treatment of high calcium levels associated with cancer that has not responded to bisphosphonates. Wyost is an interchangeable biosimilar to Xgeva (denosumab).
Letybo
Mar 4, 2024 - Letybo (letibotulinumtoxinA-wlbg) is injected into muscles to temporarily improve the appearance of moderate to severe brow furrows (glabellar lines) in adults. These frown lines are typically associated with corrugator and/or procerus muscle activity.
Simlandi
Feb 26, 2024 - Simlandi (adalimumab-ryvk) is a tumor necrosis factor (TNF) blocker interchangeable biosimilar to Humira, approved for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis.
Amtagvi
Feb 19, 2024 - Amtagvi (lifileucel) is a type of medicine called “tumor-derived autologous T cell immunotherapy” that is given as an infusion into your vein (usually in a hospital). It may be used to treat adults with melanoma that cannot be surgically removed or has spread to other parts of the body AND has not responded or has stopped responding to a PD-1 blocking drug either by itself or in a combination AND, if BRAF V600 mutation-positive, has not responded to a BRAF inhibitor with or without a MEK inhibitor.